Hangzhou Weibeny Pharmaceutical

Hangzhou Weibeny Pharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses on metabolic and inflammatory diseases, with a robust pipeline targeting conditions such as gout, hyperuricemia, and non-alcoholic steatohepatitis (NASH). Its lead asset, WB007, is a potent URAT1 inhibitor designed to treat chronic gout by promoting uric acid excretion. Additionally, the company is advancing WB001, a thyroid hormone receptor beta (THR-beta) agonist for the treatment of NASH/MASH. Weibeny is supported by leading venture capital firms including Qiming Venture Partners and HighLight Capital. The company leverages its expertise in medicinal chemistry to develop high-quality drug candidates with improved safety and efficacy profiles.